

RSC-BMCS 9th Fragment-based Drug Discovery meeting

Poster listing

Poster number	Abstract Title	Authors First name	Authors Last name	Affiliation	Country
P01	Shining A New Light on Spirocyclic Amine Synthesis for FBDD	Alexander	Cresswell	University of Bath	UK
P03	Covalent Discovery at AstraZeneca: Delivering the Next Generation of Irreversible Medicines	Henry	Blackwell	AstraZeneca	UK
P04	Design, synthesis and structural characterization of potent inhibitors of Plasmodium protein in malaria parasite.	Solène	Audebert	CBS	France
P05	Fighting the resistance to aminoglycosides - design of bacterial enzyme inhibitors	Jean-Francois	Guichou	AGVDiscovery	France
P06	Applying a new drug discovery platform for the discovery and development of inhibitors of DNA Damage Response proteins APE1 and Pol eta	Debanu	Das	XPose Therapeutics Inc	USA
P07	A knowledge-based design platform to enhance FBDD and chemoproteomics outcomes	Greg	Makara	ChemPass	Hungary
P08	An in-silico platform for rapid automated generative fragment growing and optimization	Greg	Makara	ChemPass	Hungary
P09	Target Validation of Bacterial E3 Ligases Using Chemical and Structural Biology	Cassandra	Kennedy	The Francis Crick Institute	UK
P10	Fragment Screening at AstraZeneca: Library Design and Ideology	Simon	Lucas	AstraZeneca	UK
P11	Charting an atlas of bioactive chemical space for Gram-negative bacteria	Calum	Evans	Francis Crick Institute	UK
P12	Establishing a cyclin-dependent kinase 8 fragment library for optimizing a consensus machine learning model for the curation of a focused screening library	Tony	Lin	Taipei Medical University	Taiwan
P13	DragonFold: A Deep Learning Protein-Ligand Co-Folding Platform for Fragment-to-Lead Drug Discovery	Geoffrey	Smith	CHARM Therapeutics	UK

Poster number	Abstract Title	Authors First name	Authors Last name	Affiliation	Country
P14	Chemical Biology Approaches to Explore the Ligandability of TRIM E3 Ligases	Katherine	McPhie	The Francis Crick Institute	UK
P15	Design and Crystallographic Screening of a Highly Sociable and Diverse Fragment Library	Philipp	Janssen	University of Muenster	Germany
P16	Reactive Fragments to Discover Novel Protein Degradors	Rebecca	Midgley	GSK/University of Strathclyde	UK
P17	Development of antiviral toolbox compounds targeting the Nsp3 Macrodomein 1 of SARS-CoV-2	Jasmin Cara	Aschenbrenner	Diamond Light Source	UK
P18	The AI-driven Structure-enabled Antiviral Platform (ASAP): Accelerating drug discovery and development through crystallographic fragment screening.	Blake	Balcomb	Diamond Light Source Ltd	UK
P19	Fragments at CRH: Where we are, and where we plan to go.	Stuart	Davidson	Cancer Research Horizons	UK
P20	Covering an untapped chemical space with sp ² -sp ³ hybrid (covalent) fragments	Raquel	Mato	Spirochem AG	Switzerland
P21	A structure-guided, fragment-based approach to developing novel splicing modulators	Imogen	Andrews	The Institute of Cancer Research	UK
P22	Fragment screening of G-protein-coupled receptors using Grating-Coupled Interferometry (GCI) technology	Edoardo	Fabini	Evotec UK	UK
P23	Identifying and Optimising New Chemotypes for BRPF1b Inhibition with Grating-Coupled Interferometry	Stuart	Cameron	Concept Life Sciences	UK
P24	Covalent fragment-based drug discovery workflow demonstrated on Bruton's Tyrosine Kinase	Moran	Jerabek-Willem	CRELUX GmbH - a WuXi AppTec company	Germany
P25	X-ray crystallographic fragment screening for the identification of allosteric binding sites	Jiyan	Mandrup Kandemir	Astex Pharmaceuticals	UK
P26	Advancing Fragment-Based Drug Discovery in the ASAP Consortium with Fragmenstein	Matteo	Paolo Ferla	University of Oxford	UK
P27	Synthesis and Vectorial Functionalisation of Pyrazolo[3,4-c]pyridines for Fragment-based Drug Discovery	Elizabeth	Bedwell	Durham University	UK

Poster number	Abstract Title	Authors First name	Authors Last name	Affiliation	Country
P28	Fragment Library Design at Astex	Juan	Bueren-Calabuig	Astex Pharmaceuticals	UK
P29	Large-scale in silico Fragment Screening Based on Absolute Free Energy Perturbation (AB-FEP+)	Gang	Wang	Schrodinger	USA
P30	FraGrow: Fully automated software for fragment hit to lead growth and optimization	Peter	Ibrahim	University of Dundee	UK
P31	The Development of Next-Generation Reactive Electrophiles for Beyond Cysteine Covalent Drug Discovery	Alfred	Doherty	GSK	UK
P32	Title Fragment-Based approach towards allosteric modulators of β -Glucocerebrosidase	Nicholas	Palmer	Astex Pharmaceuticals	UK
P33	FBDD approaches to tackle emerging multi-component therapeutic targets	Juliet	Morgan	Sygnature Discovery	UK
P34	Identifying novel CDK9 inhibitors via an efficient virtual screening workflow	Kirill	Popov	Red Glead Discovery	Sweden
P35	Computational tools for fast and streamlined analysis of protein flexibility in the context of drug design	Melanie	Schneider	EMBL	France
P36	Identification of covalent fragment hits via Ultra-High Throughput Mass Spectrometry Screening	William	Mahy	MSD	UK
P37	A 'direct-to-biology' platform for the rapid identification and optimisation of novel, irreversible antivirals	Harry	Wilders	GSK/University of Strathclyde	UK
P38	HIPPO: An interaction-based multi-objective optimiser for selecting the most effective experiments for structural based drug-discovery campaigns	Max	Winokan	Diamond Light Source	UK
P39	Fragment Binding Sites, Poses and Affinities with Grand Canonical Nonequilibrium Candidate Monte Carlo	William	Poole	University of Southampton	UK
P40	Screening for Fragment Molecular Glues	Pim	de Vink	Zobio B.V.	Netherlands
P41	Specific inhibition of CK2 α from an anchor outside the active site	Paul	Brear	University of Cambridge	UK

Poster number	Abstract Title	Authors First name	Authors Last name	Affiliation	Country
P42	Crystal based lead identification by fast fragment and compound screening at the Paul Scherrer Institute: Swiss Light Source and SwissFEL	Dennis	Stegmann	Paul Scherrer Institute	Switzerland
P43	Strategies towards novel inhibitor classes and small molecule modulators acting on AAA+ ATPase p97	Sebastian	Bothe	University of Würzburg	Germany
P44	Targeting UBA6: finding a covalent inhibitor through fragment tethering and diversity library screening	Regina	Wirsing	University Würzburg	Germany
P45	SILVR: Guided Diffusion for Molecule Generation	Nicholas	Runcie	University of Edinburgh / AstraZeneca	UK
P46	Synthesis and Evaluation of New Cys-focused Binders against Aldehyde Dehydrogenase 1A1 (ALDH1A1) and its Intrinsic Reactivity	Tetiana	Matviyuk	Enamine	Ukraine
P47	Too weak for biophysics: Concentration-dependent crystallographic soaking as tool for fragment hit prioritisation.	Yuliya	Dubianok	Sanofi	France
P48	Biosensor-based strategies for identifying fragment hits for challenging targets	Helena	Danielson	Uppsala University	Sweden
P49	A General Learning Framework for Reviving Large Non-Parametric SPR Fragment PPI Datasets	Bruce	Carrington	Slough	UK
P50	Application of fragment-based, structure-first approach to discover new PYCR1 inhibitors	Olga	Tarkhanova	Kyiv	Ukraine